Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 19/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.73 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | TTK | P33981 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429993 | 1.00 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL18018932 | 0.94 | LRRK2 (0.88) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL18018906 | 0.91 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL17980593 | 0.90 | LRRK2 (0.81) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL18018902 | 0.90 | LRRK2 (1.00) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL22264283 | 0.89 | TTK (0.82) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL22264303 | 0.89 | LRRK2 (0.79) | LRRK2TTK | |
| SCHEMBL21738312 | 0.87 | LRRK2 (0.78) | LRRK2MAP3K9MKNK2TTK | |
| SCHEMBL19921205 | 0.87 | LRRK2 (0.78) | LRRK2MAP3K9MKNK2JAK2TTK | |
| SCHEMBL24556862 | 0.86 | LRRK2 (0.77) | LRRK2MAP3K9MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-114945378-B | Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells and related uses thereof | 休斯敦大学体系 | 2024-11-19 | — | — | CN | disclosed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| CN-114945378-A | Feeder-layer and feeder-layer-free stem cell culture systems for stratified epithelial stem cells and uses related thereto | 休斯敦大学体系 | 2022-08-26 | — | — | CN | disclosed |
| US-20220088021-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | LOXO ONCOLOGY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-11046720-B2 | Dimethylphosphine oxide compound | Guizhou Inochini Technology Co., Ltd (CN) | 2021-06-29 | — | — | US | disclosed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210147453-A1 | DIMETHYLPHOSPHINE OXIDE COMPOUND | Guizhou Inochini Technology Co., Ltd (CN) | 2021-05-20 | — | — | US | disclosed |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3322706-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180119228-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-05-03 | — | — | US | disclosed |
| EP-3303631-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | Loxo Oncology Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180030548-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20180030549-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2016196671-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | LOXO ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030548-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | LRRK2 2089/4885MAP3K9 106/4885MKNK2 239/4885 |
| US-20180119228-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | LRRK2 1922/4885MAP3K9 102/4885MKNK2 232/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | LRRK2 2089/4885MAP3K9 106/4885MKNK2 239/4885 |
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | LRRK2 1/4885MAP3K9 284/4885MKNK2 138/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | LRRK2 315/4885MAP3K9 21/4885MKNK2 373/4885 |
| US-20220088021-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | NTRK3, NTRK1, NTRK2 | LRRK2 3256/4885MAP3K9 100/4885MKNK2 323/4885 |
| US-11046720-B2 | Dimethylphosphine oxide compound | LRRK2, PDPK1, PARK7 | LRRK2 1/4885MAP3K9 13/4885MKNK2 21/4885 |
| US-20180030549-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | LRRK2 2089/4885MAP3K9 106/4885MKNK2 239/4885 |
| US-20210147453-A1 | DIMETHYLPHOSPHINE OXIDE COMPOUND | LRRK2, PDPK1, PARK7 | LRRK2 1/4885MAP3K9 13/4885MKNK2 21/4885 |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | LRRK2 1922/4885MAP3K9 102/4885MKNK2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.